ZA976612B - Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission. - Google Patents

Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission.

Info

Publication number
ZA976612B
ZA976612B ZA9706612A ZA976612A ZA976612B ZA 976612 B ZA976612 B ZA 976612B ZA 9706612 A ZA9706612 A ZA 9706612A ZA 976612 A ZA976612 A ZA 976612A ZA 976612 B ZA976612 B ZA 976612B
Authority
ZA
South Africa
Prior art keywords
excitotoxicity
pyrido
malfunctioning
disorders associated
neurological disorders
Prior art date
Application number
ZA9706612A
Other languages
English (en)
Inventor
Wojciech Danysz
Markus Gold
Ivars Kalvinsh
Christopher Graham Rap Parsons
Irene Piskunova
Eugene Rozhkov
Original Assignee
Merz & Co Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz & Co Gmbh & Co filed Critical Merz & Co Gmbh & Co
Publication of ZA976612B publication Critical patent/ZA976612B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ZA9706612A 1996-07-25 1997-07-24 Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission. ZA976612B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/686,346 US5776935A (en) 1996-07-25 1996-07-25 Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission

Publications (1)

Publication Number Publication Date
ZA976612B true ZA976612B (en) 1998-02-10

Family

ID=24755940

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9706612A ZA976612B (en) 1996-07-25 1997-07-24 Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission.

Country Status (31)

Country Link
US (1) US5776935A (cs)
EP (1) EP0931081B1 (cs)
JP (1) JP3595342B2 (cs)
KR (1) KR100598206B1 (cs)
CN (1) CN1093860C (cs)
AR (1) AR004158A1 (cs)
AT (1) ATE224894T1 (cs)
AU (1) AU719993B2 (cs)
BR (1) BR9710569A (cs)
CA (1) CA2261923C (cs)
CZ (1) CZ289293B6 (cs)
DE (1) DE69715893T2 (cs)
DK (1) DK0931081T3 (cs)
EA (1) EA001711B1 (cs)
ES (1) ES2180041T3 (cs)
FI (1) FI112946B (cs)
GE (1) GEP20022801B (cs)
HK (1) HK1020193A1 (cs)
HU (1) HU223780B1 (cs)
IL (1) IL128225A (cs)
LT (1) LT4591B (cs)
LV (1) LV12260B (cs)
NO (1) NO310820B1 (cs)
PL (1) PL189572B1 (cs)
PT (1) PT931081E (cs)
SI (1) SI9720048B (cs)
SK (1) SK283536B6 (cs)
TW (1) TW402605B (cs)
UA (1) UA63911C2 (cs)
WO (1) WO1998004556A1 (cs)
ZA (1) ZA976612B (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
EP1427404A4 (en) * 2001-08-20 2005-10-26 Maiken Nedergaard TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS
EP1298581A1 (fr) * 2001-09-27 2003-04-02 C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal
US7105185B2 (en) 2001-10-03 2006-09-12 Herbalscience, Llc Kavalactone profile
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US7001620B2 (en) 2001-10-03 2006-02-21 Herbal Science, Llc Kavalactone product
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
US7029707B2 (en) * 2001-10-03 2006-04-18 Herbalscience, Llc Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7294353B2 (en) * 2003-10-24 2007-11-13 Herbalscience, Llc Methods and compositions comprising ilex
CN1917892A (zh) * 2003-10-24 2007-02-21 草本制药科学有限责任公司 包含冬青的方法和组合物
SG161256A1 (en) * 2005-04-08 2010-05-27 Abbott Lab Oral pharmaceutical formulations comprising fenofibric acid and/or its salts
BRPI0815957A2 (pt) * 2007-09-20 2019-09-24 Cortex Pharma Inc "composto, composição farmacêutica, métodos e respectivo uso de 1,2,3-triazin-4-onas trissubstituídas e 1,3-pirimidinonas trissubstituídas para a melhora das respostas sinápticas glutamatérgicas"
EP2264035A1 (en) * 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AU2018284335A1 (en) 2017-06-12 2020-01-30 Glytech Llc. Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists
USD895157S1 (en) 2018-03-06 2020-09-01 IsoTruss Indsutries LLC Longitudinal beam
CN109912503B (zh) * 2019-04-01 2022-04-08 江南大学 一种2,3-二酰基喹啉类化合物的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
US5597922A (en) * 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore

Also Published As

Publication number Publication date
IL128225A0 (en) 1999-11-30
CN1093860C (zh) 2002-11-06
LT4591B (lt) 1999-12-27
AR004158A1 (es) 1998-11-04
CN1228778A (zh) 1999-09-15
NO990306L (no) 1999-03-15
NO990306D0 (no) 1999-01-22
IL128225A (en) 2005-09-25
JP2000515872A (ja) 2000-11-28
HUP9903104A2 (hu) 2000-03-28
BR9710569A (pt) 1999-08-17
SI9720048B (sl) 2002-02-28
NO310820B1 (no) 2001-09-03
ES2180041T3 (es) 2003-02-01
EP0931081B1 (en) 2002-09-25
DE69715893T2 (de) 2003-01-30
HK1020193A1 (en) 2000-03-31
SI9720048A (sl) 1999-12-31
DE69715893D1 (de) 2002-10-31
AU719993B2 (en) 2000-05-18
FI990134A0 (fi) 1999-01-25
EA199900161A1 (ru) 1999-10-28
KR100598206B1 (ko) 2006-07-07
DK0931081T3 (da) 2003-01-27
CZ289293B6 (cs) 2001-12-12
CA2261923C (en) 2006-01-24
UA63911C2 (uk) 2004-02-16
CZ2019997A3 (cs) 1999-09-15
FI112946B (fi) 2004-02-13
GEP20022801B (en) 2002-09-25
FI990134A (fi) 1999-03-24
EP0931081A1 (en) 1999-07-28
JP3595342B2 (ja) 2004-12-02
HUP9903104A3 (en) 2000-04-28
LV12260A (lv) 1999-04-20
AU4296997A (en) 1998-02-20
LV12260B (en) 1999-08-20
KR20000029568A (ko) 2000-05-25
SK283536B6 (sk) 2003-09-11
PL189572B1 (pl) 2005-08-31
LT99007A (en) 1999-07-26
PL331323A1 (en) 1999-07-05
CA2261923A1 (en) 1998-02-05
SK10399A3 (en) 2000-01-18
EA001711B1 (ru) 2001-06-25
ATE224894T1 (de) 2002-10-15
TW402605B (en) 2000-08-21
HU223780B1 (hu) 2005-01-28
PT931081E (pt) 2003-02-28
WO1998004556A1 (en) 1998-02-05
US5776935A (en) 1998-07-07

Similar Documents

Publication Publication Date Title
ZA976612B (en) Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission.
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
AU6396598A (en) Arylsulphonamides and analogues and their use for the treatment and neurovegetative disorders
HUP0004439A3 (en) 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
IL128800A0 (en) 4-Heteroylpyrazol derivatives and the use thereof as herbicides
IL125376A0 (en) Fixture and prosthesis including the same
AU3339897A (en) Sulphonamide derivatives and their use in the treatment of cns disorders
AU2182095A (en) Disengageable descender with self-locking of the rope
ZA975248B (en) Flow inverting homogenizer assembly.
IL150022A0 (en) Imidazo [1,3,5] triazinones and the use thereof
HUP0003298A3 (en) Branched chain fatty acids, their derivatives and use in the treatment of central nervous system disorders
ZA958595B (en) UV absorbers their preparation and the use thereof
BR9707922A (pt) Cafeína e clemastina para tratamento de distúrbios respiratórios
World Health Organization Guidelines for the primary prevention of mental, neurological and psychosocial disorders. 5. Staff burnout
HUP9904032A3 (en) 1,2,4-benzothiadiazine derivatives,their preparation and use
AU7401598A (en) Epoxide-amine dendrimers and the preparation and use thereof
EP1126850A4 (en) TREATMENT OF CONDITIONS OF THE RETINA
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
AU7624598A (en) 1,4-diazabicyclo (2.2.2) Oct-2-ylmethyl derivatives, their preparation and the rapeutic application
BR9712030A (pt) Uso de benzopiranÄis para o tratamento de desordens neurolÄgicas
ZA976479B (en) Alfa-amino acids amides, preparation thereof and the therapeutical use thereof.
AU6281298A (en) Use of lofexidine in the treatment of behavioral disorders
ZA973843B (en) Treatment of asthma with TNFR-lg.
GB9604319D0 (en) The Coleman-Sims safety valve
EP0786248A3 (fr) Utilisation du dithioacétate de S,S'-éthylidène à titre d'ingrédient parfumant et aromatisant